fesoterodine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4191 286930-02-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fesoterodine
  • toviaz
  • fesoterodine fumarate
a muscarinic antagonist for treatment of overactive bladder
  • Molecular weight: 411.59
  • Formula: C26H37NO3
  • CLOGP: 4.36
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -5.30
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O
3.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 256 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.33 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 64
kinase-selectivity-class ACVRL1,AXL,BRAF,EIF2AK3,EPHB4,PDK4 6
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 2008 FDA PFIZER
April 20, 2007 EMA Pfizer Europe MA EEIG
Dec. 25, 2012 PMDA PFIZER JAPAN INC.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 245.58 17.94 108 10156 37636 90580547
Dry mouth 134.94 17.94 133 10131 183926 90434257
Fall 127.41 17.94 209 10055 481601 90136582
Brain injury 106.19 17.94 38 10226 7700 90610483
Carbuncle 101.07 17.94 25 10239 1411 90616772
Monoclonal immunoglobulin present 91.36 17.94 25 10239 2099 90616084
Hypothalamo-pituitary disorder 89.91 17.94 25 10239 2227 90615956
Body height decreased 83.53 17.94 36 10228 11913 90606270
Multiple fractures 77.48 17.94 32 10232 9530 90608653
Pulseless electrical activity 76.15 17.94 31 10233 8901 90609282
Urinary incontinence 75.10 17.94 49 10215 37517 90580666
Overweight 73.42 17.94 27 10237 5907 90612276
Fibrosis 66.04 17.94 25 10239 5927 90612256
Electrocardiogram QRS complex prolonged 60.93 17.94 25 10239 7323 90610860
Wrist deformity 60.36 17.94 20 10244 3218 90614965
Gait disturbance 56.81 17.94 104 10160 260392 90357791
Dyslipidaemia 56.37 17.94 26 10238 10081 90608102
Renal cyst 56.08 17.94 28 10236 12922 90605261
Catarrh 55.55 17.94 16 10248 1618 90616565
Nephropathy 55.42 17.94 25 10239 9210 90608973
Dysuria 54.46 17.94 41 10223 39360 90578823
Dysstasia 53.33 17.94 34 10230 25018 90593165
Burns second degree 48.28 17.94 15 10249 1965 90616218
Purpura 47.02 17.94 26 10238 14752 90603431
Steroid dependence 46.27 17.94 15 10249 2254 90615929
Bone density decreased 40.58 17.94 25 10239 17320 90600863
Vertigo 37.79 17.94 43 10221 69768 90548415
Limb injury 37.48 17.94 30 10234 31478 90586705
Hypopnoea 36.48 17.94 15 10249 4416 90613767
Bradycardia 34.57 17.94 45 10219 83802 90534381
Gingival pain 33.53 17.94 18 10246 9634 90608549
Movement disorder 33.18 17.94 27 10237 28992 90589191
Constipation 31.58 17.94 86 10178 280309 90337874
Arthritis 30.53 17.94 62 10202 167253 90450930
Skin disorder 27.70 17.94 27 10237 36679 90581504
Colitis ulcerative 27.46 17.94 34 10230 60232 90557951
Nocturia 27.14 17.94 16 10248 10239 90607944
Colitis ischaemic 26.88 17.94 17 10247 12329 90605854
Forced expiratory volume decreased 26.46 17.94 13 10251 5795 90612388
Finger deformity 26.34 17.94 25 10239 32872 90585311
Hepatic steatosis 25.70 17.94 26 10238 36919 90581264
Tubulointerstitial nephritis 25.70 17.94 22 10242 25321 90592862
Loss of consciousness 25.62 17.94 52 10212 140186 90477997
Dry throat 25.31 17.94 14 10250 7946 90610237
Bladder spasm 24.24 17.94 9 10255 2021 90616162
Frequent bowel movements 24.15 17.94 31 10233 56904 90561279
Parosmia 24.04 17.94 13 10251 7056 90611127
Micturition urgency 23.29 17.94 15 10249 11218 90606965
Cardiac murmur 23.09 17.94 18 10246 18176 90600007
Multiple sclerosis relapse 23.01 17.94 29 10235 52276 90565907
Cholelithiasis 22.92 17.94 29 10235 52477 90565706
Tinnitus 22.39 17.94 26 10238 43076 90575107
Decreased activity 22.25 17.94 13 10251 8179 90610004
Haemorrhagic stroke 22.24 17.94 12 10252 6484 90611699
Pulmonary embolism 22.13 17.94 47 10217 130773 90487410
Rectal haemorrhage 21.86 17.94 36 10228 82708 90535475
Infusion related reaction 21.75 17.94 10 10254 416770 90201413
Anticholinergic syndrome 21.61 17.94 9 10255 2734 90615449
Swollen tongue 21.05 17.94 26 10238 45930 90572253
Diabetes mellitus 21.00 17.94 31 10233 64844 90553339
Psychiatric decompensation 20.97 17.94 8 10256 1935 90616248
Dementia 20.77 17.94 19 10245 23842 90594341
Rhinitis 20.72 17.94 15 10249 13557 90604626
Blood immunoglobulin E increased 20.44 17.94 10 10254 4415 90613768
Nightmare 20.29 17.94 18 10246 21707 90596476
Urinary tract infection 20.08 17.94 78 10186 305554 90312629
Fracture 20.04 17.94 18 10246 22058 90596125
Foot deformity 20.03 17.94 29 10235 59622 90558561
Treatment failure 19.82 17.94 5 10259 303923 90314260
Wound 19.73 17.94 5 10259 302975 90315208
Stress 19.62 17.94 34 10230 81361 90536822
Feeling abnormal 19.51 17.94 52 10212 167183 90451000
Product blister packaging issue 19.34 17.94 5 10259 337 90617846
Ear pruritus 19.02 17.94 11 10253 6792 90611391
Pollakiuria 19.00 17.94 21 10243 32984 90585199
Stomatitis 18.94 17.94 4 10260 274694 90343489

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary retention 330.11 28.66 157 7384 42057 42571737
Catarrh 263.11 28.66 79 7462 5907 42607887
Burns second degree 261.69 28.66 79 7462 6017 42607777
Steroid dependence 254.08 28.66 79 7462 6643 42607151
Parosmia 243.61 28.66 79 7462 7612 42606182
Hypopnoea 241.71 28.66 79 7462 7803 42605991
Gingival pain 239.89 28.66 80 7461 8414 42605380
Systemic lupus erythematosus 228.69 28.66 79 7462 9245 42604549
Rhinitis 205.75 28.66 78 7463 11899 42601895
Cardiac murmur 204.42 28.66 79 7462 12696 42601098
Impaired work ability 194.27 28.66 75 7466 12016 42601778
Bronchiectasis 181.39 28.66 80 7461 17939 42595855
Swollen tongue 181.20 28.66 84 7457 21147 42592647
Alcohol poisoning 169.67 28.66 60 7481 7514 42606280
Frequent bowel movements 168.20 28.66 80 7461 21327 42592467
Migraine 163.90 28.66 83 7458 25331 42588463
Impaired quality of life 162.50 28.66 69 7472 14108 42599686
Colitis ulcerative 158.69 28.66 82 7459 26093 42587701
Nightmare 156.38 28.66 80 7461 24932 42588862
Accidental overdose 152.58 28.66 82 7459 28248 42585546
Vertigo 151.05 28.66 87 7454 34260 42579534
Tinnitus 148.17 28.66 81 7460 28857 42584937
Eczema 138.42 28.66 82 7459 34004 42579790
Dysgeusia 132.98 28.66 80 7461 34109 42579685
Rectal haemorrhage 131.05 28.66 91 7450 49515 42564279
Tubulointerstitial nephritis 130.99 28.66 77 7464 31471 42582323
Medication error 130.04 28.66 78 7463 33076 42580718
Arthritis 120.17 28.66 81 7460 41984 42571810
Stress 118.87 28.66 82 7459 44130 42569664
Palpitations 117.61 28.66 86 7455 50711 42563083
Loss of personal independence in daily activities 110.06 28.66 82 7459 49734 42564060
Confusional state 103.09 28.66 137 7404 167460 42446334
Haematochezia 98.49 28.66 82 7459 58354 42555440
Intentional product use issue 87.68 28.66 84 7457 71749 42542045
Adverse drug reaction 83.49 28.66 62 7479 37372 42576422
Abdominal discomfort 80.69 28.66 82 7459 75173 42538621
Cerebrovascular accident 79.89 28.66 92 7449 97068 42516726
Deep vein thrombosis 77.36 28.66 81 7460 76876 42536918
Depression 71.38 28.66 93 7448 111270 42502524
COVID-19 68.43 28.66 93 7448 115855 42497939
Somnolence 65.51 28.66 101 7440 141004 42472790
Dry mouth 65.15 28.66 55 7486 39824 42573970
Inappropriate schedule of product administration 64.43 28.66 82 7459 95820 42517974
Pulmonary embolism 53.23 28.66 84 7457 119528 42494266
Weight decreased 42.21 28.66 105 7436 207843 42405951
Pain in extremity 40.47 28.66 85 7456 150519 42463275
Product use in unapproved indication 37.27 28.66 93 7448 184363 42429431
Dysuria 33.48 28.66 34 7507 31062 42582732
Traumatic haemothorax 29.62 28.66 8 7533 406 42613388

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Catarrh 324.05 17.73 93 15956 7242 110566008
Burns second degree 314.78 17.73 92 15957 7641 110565609
Steroid dependence 306.52 17.73 92 15957 8377 110564873
Hypopnoea 279.76 17.73 92 15957 11288 110561962
Urinary retention 278.86 17.73 155 15894 69528 110503722
Parosmia 266.51 17.73 92 15957 13088 110560162
Gingival pain 265.46 17.73 96 15953 15640 110557610
Cardiac murmur 217.17 17.73 94 15955 24534 110548716
Rhinitis 215.14 17.73 91 15958 22454 110550796
Impaired work ability 185.54 17.73 86 15963 26333 110546917
Nightmare 179.17 17.73 95 15954 38768 110534482
Bronchiectasis 179.04 17.73 93 15956 36400 110536850
Alcohol poisoning 178.61 17.73 62 15987 8958 110564292
Vertigo 172.46 17.73 124 15925 86746 110486504
Impaired quality of life 166.17 17.73 83 15966 29934 110543316
Swollen tongue 164.85 17.73 105 15944 60257 110512993
Colitis ulcerative 159.47 17.73 113 15936 77250 110496000
Frequent bowel movements 158.18 17.73 109 15940 71281 110501969
Accidental overdose 156.23 17.73 96 15953 51738 110521512
Tinnitus 152.25 17.73 100 15949 60440 110512810
Tubulointerstitial nephritis 149.65 17.73 95 15954 54189 110519061
Rectal haemorrhage 135.36 17.73 123 15926 119710 110453540
Dysgeusia 132.28 17.73 97 15952 69888 110503362
Eczema 129.47 17.73 97 15952 72196 110501054
Fall 124.90 17.73 272 15777 603210 109970040
Arthritis 124.54 17.73 137 15912 167449 110405801
Stress 122.64 17.73 110 15939 105238 110468012
Medication error 105.19 17.73 101 15948 105265 110467985
Haematochezia 95.57 17.73 100 15949 115424 110457826
Carbuncle 94.38 17.73 25 16024 1442 110571808
Palpitations 92.93 17.73 115 15934 159097 110414153
Dry mouth 86.86 17.73 125 15924 199823 110373427
Pulmonary embolism 83.00 17.73 127 15922 214347 110358903
Body height decreased 82.37 17.73 37 16012 10526 110562724
Deep vein thrombosis 81.56 17.73 101 15948 139786 110433464
Cerebrovascular accident 81.18 17.73 115 15934 181169 110392081
Monoclonal immunoglobulin present 80.81 17.73 25 16024 2515 110570735
Loss of personal independence in daily activities 79.05 17.73 103 15946 149917 110423333
Hypothalamo-pituitary disorder 78.01 17.73 25 16024 2821 110570429
Brain injury 76.74 17.73 38 16011 13438 110559812
Multiple fractures 71.90 17.73 32 16017 8908 110564342
Migraine 69.73 17.73 104 15945 171548 110401702
Confusional state 68.56 17.73 185 15864 468495 110104755
Overweight 64.67 17.73 27 16022 6437 110566813
Intentional product use issue 64.42 17.73 123 15926 247783 110325467
Adverse drug reaction 64.40 17.73 78 15971 105481 110467769
Inappropriate schedule of product administration 64.33 17.73 110 15939 203527 110369723
COVID-19 62.95 17.73 121 15928 244939 110328311
Somnolence 60.08 17.73 133 15916 297316 110275934
Wrist deformity 55.80 17.73 20 16029 3169 110570081
Pulseless electrical activity 55.52 17.73 33 16016 16724 110556526
Depression 54.35 17.73 133 15916 317202 110256048
Fibrosis 54.01 17.73 25 16024 7617 110565633
Dysuria 49.53 17.73 52 15997 60179 110513071
Dysstasia 47.63 17.73 39 16010 32947 110540303
Urinary incontinence 47.37 17.73 46 16003 48541 110524709
Nephropathy 40.69 17.73 25 16024 13442 110559808
Weight decreased 40.21 17.73 154 15895 467903 110105347
Gait disturbance 39.78 17.73 109 15940 278099 110295151
Dyslipidaemia 39.20 17.73 26 16023 15939 110557311
Electrocardiogram QRS complex prolonged 38.91 17.73 24 16025 12997 110560253
Bone density decreased 36.69 17.73 25 16024 16017 110557233
Renal cyst 36.15 17.73 26 16023 18146 110555104
Colitis ischaemic 34.41 17.73 25 16024 17725 110555525
Hypertonic bladder 33.33 17.73 16 16033 5286 110567964
Movement disorder 30.95 17.73 32 16017 36372 110536878
Product use in unapproved indication 30.39 17.73 137 15912 447240 110126010
Systemic lupus erythematosus 29.95 17.73 93 15956 254245 110319005
Cystitis interstitial 28.67 17.73 10 16039 1464 110571786
Infusion related reaction 28.28 17.73 10 16039 381152 110192098
Thrombocytopenia 27.93 17.73 8 16041 348877 110224373
Purpura 27.43 17.73 25 16024 24363 110548887
Treatment failure 27.04 17.73 4 16045 277230 110296020
Anaemia 26.78 17.73 24 16025 547062 110026188
Limb injury 26.58 17.73 30 16019 37606 110535644
Traumatic haemothorax 26.26 17.73 8 16041 764 110572486
Toxicity to various agents 26.11 17.73 19 16030 480536 110092714
Dementia 25.42 17.73 27 16022 31646 110541604
Pneumonia 23.82 17.73 58 15991 876656 109696594
Infection 22.89 17.73 12 16037 362188 110211062
Drug intolerance 22.17 17.73 16 16033 406496 110166754
Diarrhoea 22.04 17.73 88 15961 1139417 109433833
Stomatitis 21.99 17.73 6 16043 270236 110303014
Abdominal discomfort 21.27 17.73 113 15936 393745 110179505
Nausea 21.12 17.73 100 15949 1235590 109337660
Finger deformity 21.06 17.73 25 16024 33067 110540183
Alopecia 20.36 17.73 14 16035 364739 110208511
Pain in extremity 20.00 17.73 130 15919 486988 110086262
Emphysematous pyelonephritis 19.71 17.73 6 16043 572 110572678
Cholelithiasis 19.65 17.73 34 16015 63388 110509862
Contraindicated product administered 19.30 17.73 6 16043 248261 110324989
Swelling 18.90 17.73 14 16035 351027 110222223
Skin disorder 18.85 17.73 27 16022 42886 110530364
Joint swelling 18.74 17.73 22 16027 442823 110130427
Urinary tract infection 18.57 17.73 95 15954 326187 110247063
Nocturia 18.30 17.73 17 16032 16973 110556277
Urine flow decreased 17.95 17.73 7 16042 1399 110571851
Product blister packaging issue 17.89 17.73 5 16044 353 110572897

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD11 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
ATC G04BD13 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35846 renal agent

Related Drugs by ATC class:

G04BD Drugs for urinary frequency and incontinence 13 drugs
darifenacinemeproniumflavoxateimidafenacinmeladrazinemirabegronoxybutyninpropiverinesolifenacinterodilinetolterodinetrospium show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Myasthenia gravis contraindication 91637004 DOID:437
Acute constipation contraindication 197119006
Bladder outflow obstruction contraindication 236645006
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Aggravated Glaucoma contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.64 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 7807715 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
4MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 8088398 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 7807715 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
8MG TOVIAZ PFIZER N022030 Oct. 31, 2008 RX TABLET, EXTENDED RELEASE ORAL 8088398 June 7, 2027 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.40 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 6.27 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 6.39 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 6.19 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 5.98 WOMBAT-PK

External reference:

IDSource
4028101 VUID
N0000179802 NUI
D07226 KEGG_DRUG
286930-03-8 SECONDARY_CAS_RN
4028101 VANDF
4028102 VANDF
C2343853 UMLSCUI
CHEBI:135920 CHEBI
CHEMBL1201764 ChEMBL_ID
CHEMBL1201765 ChEMBL_ID
DB06702 DRUGBANK_ID
C526675 MESH_SUPPLEMENTAL_RECORD_UI
7473 IUPHAR_LIGAND_ID
8068 INN_ID
621G617227 UNII
6918558 PUBCHEM_CID
DB15578 DRUGBANK_ID
797195 RXNORM
137285 MMSL
25992 MMSL
358891 MMSL
399949 MMSL
d07162 MMSL
012671 NDDF
012672 NDDF
36571000122101 SNOMEDCT_US
432254002 SNOMEDCT_US
432255001 SNOMEDCT_US
441469003 SNOMEDCT_US
C4301611 UMLSCUI
CHEMBL3348932 ChEMBL_ID
207679-81-0 SECONDARY_CAS_RN
9819382 PUBCHEM_CID
10020 INN_ID
YU871O78GR UNII
CHEBI:177454 CHEBI
621G617227 INXIGHT DRUGS
YU871O78GR INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 29 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 0069-0244 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 29 sections
FESOTERODINE FUMARATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-033 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
FESOTERODINE FUMARATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-034 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 43598-247 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 43598-248 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 46708-175 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 46708-176 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 51407-661 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
Fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 51407-662 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 54868-6156 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 29 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 54868-6175 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 29 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 62332-175 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 62332-176 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 26 sections
Fesoterodine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 65162-369 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 19 sections
Fesoterodine Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 65162-370 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 19 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-766 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
FESOTERODINE FUMARATE Human Prescription Drug Label 1 65862-767 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 26 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 67877-064 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
Fesoterodine Fumarate Human Prescription Drug Label 1 67877-068 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 68180-618 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 27 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 68180-619 TABLET, EXTENDED RELEASE 8 mg ORAL ANDA 27 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 68382-479 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 68382-480 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 69189-0242 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 28 sections
Toviaz HUMAN PRESCRIPTION DRUG LABEL 1 69189-0244 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL NDA 28 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1168 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 1 sections
fesoterodine fumarate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1169 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 1 sections
FESOTERODINE FUMARATE HUMAN PRESCRIPTION DRUG LABEL 1 72603-413 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 25 sections
FESOTERODINE FUMARATE HUMAN PRESCRIPTION DRUG LABEL 1 72603-414 TABLET, FILM COATED, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections